{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:39:45Z","timestamp":1794299985371,"version":"4.9.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research","doi-asserted-by":"publisher","award":["MLP1804, BSC0123"],"award-info":[{"award-number":["MLP1804, BSC0123"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["GAP0091"],"award-info":[{"award-number":["GAP0091"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antiepileptic drug therapy has significant inter-patient variability in response towards it. The current study aims to understand this variability at the molecular level using microarray-based analysis of peripheral blood gene expression profiles of patients receiving valproate (VA) monotherapy. Only 10 unique genes were found to be differentially expressed in VA responders (n\u2009=\u200915) and 6 genes in the non-responders (n\u2009=\u20098) (fold-change &gt;2, p\u2009&lt;\u20090.05).<jats:italic>PTGS2<\/jats:italic>which encodes cyclooxygenase-2, COX-2, showed downregulation in the responders compared to the non-responders.<jats:italic>PTGS2\/<\/jats:italic>COX-2 mRNA profiles in the two groups corresponded to their plasma profiles of the COX-2 product, prostaglandin E<jats:sub>2<\/jats:sub>(PGE<jats:sub>2<\/jats:sub>). Since COX-2 is believed to regulate P-glycoprotein (P-gp), a multidrug efflux transporter over-expressed at the blood-brain barrier (BBB) in drug-resistant epilepsy, the pathway connecting COX-2 and P-gp was further explored<jats:italic>in vitro<\/jats:italic>. Investigation of the effect of VA upon the brain endothelial cells (hCMEC\/D3) in hyperexcitatory conditions confirmed suppression of COX-2-dependent P-gp upregulation by VA. Our findings suggest that COX-2 downregulation by VA may suppress seizure-mediated P-gp upregulation at the BBB leading to enhanced drug delivery to the brain in the responders. Our work provides insight into the association of peripheral<jats:italic>PTGS2<\/jats:italic>\/COX-2 expression with VA efficacy and the role of COX-2 as a potential therapeutic target for developing efficacious antiepileptic treatment.<\/jats:p>","DOI":"10.1038\/s41598-020-59259-x","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T11:03:11Z","timestamp":1581591791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Downregulation of peripheral PTGS2\/COX-2 in response to valproate treatment in patients with epilepsy"],"prefix":"10.1038","volume":"10","author":[{"given":"Chitra","family":"Rawat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8667-6199","authenticated-orcid":false,"given":"Rintu","family":"Kutum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiksha","family":"Kukal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujjwal Ranjan","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasis","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Saso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achal K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritushree","family":"Kukreti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"59259_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1528-1167.2009.02481.x","volume":"51","author":"AK Ngugi","year":"2010","unstructured":"Ngugi, A. K., Bottomley, C., Kleinschmidt, I., Sander, J. W. & Newton, C. R. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 51, 883\u2013890 (2010).","journal-title":"Epilepsia."},{"key":"59259_CR2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1046\/j.1528-1157.2001.04501.x","volume":"42","author":"P Kwan","year":"2001","unstructured":"Kwan, P. & Brodie, M. J. Effectiveness of first antiepileptic drug. Epilepsia. 42, 1255\u20131260 (2001).","journal-title":"Epilepsia."},{"key":"59259_CR3","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4103\/0028-3886.237000","volume":"66","author":"C Rawat","year":"2018","unstructured":"Rawat, C. et al. Clinical predictors of treatment outcome in North Indian patients on antiepileptic drug therapy: A prospective observational study. Neurol. India. 66, 1052\u20131059 (2018).","journal-title":"Neurol. India."},{"key":"59259_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1535-7511.2010.01383.x","volume":"10","author":"S Herman","year":"2010","unstructured":"Herman, S. Intractable epilepsy: relapsing, remitting, or progressive? Epilepsy Curr 10, 146\u2013148 (2010).","journal-title":"Epilepsy Curr"},{"key":"59259_CR5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1586\/ern.11.11","volume":"11","author":"M Sillanp\u00e4\u00e4","year":"2011","unstructured":"Sillanp\u00e4\u00e4, M. & Schmidt, D. Predicting antiepileptic drug response in children with epilepsy. Expert. Rev. Neurother 11, 877\u2013885 (2011).","journal-title":"Expert. Rev. Neurother"},{"key":"59259_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1528-1167.2008.01716.x","volume":"50","author":"W L\u00f6scher","year":"2009","unstructured":"L\u00f6scher, W., Klotz, U., Zimprich, F. & Schmidt, D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 50, 1\u201323 (2009).","journal-title":"Epilepsia."},{"key":"59259_CR7","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/j.1528-1167.2011.03041.x","volume":"52","author":"SD Shorvon","year":"2011","unstructured":"Shorvon, S. D. The etiologic classification of epilepsy. Epilepsia. 52, 1052\u20131057 (2011).","journal-title":"Epilepsia."},{"key":"59259_CR8","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/j.0013-9580.2004.22904.x","volume":"45","author":"NC Tan","year":"2004","unstructured":"Tan, N. C., Mulley, J. C. & Berkovic, S. F. Genetic association studies in epilepsy: \u201cthe truth is out there\u201d. Epilepsia. 45, 1429\u20131442 (2004).","journal-title":"Epilepsia."},{"key":"59259_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0920-9964(03)00151-8","volume":"67","author":"MP Vawter","year":"2004","unstructured":"Vawter, M. P. et al. Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr. Res. 67, 41\u201352 (2004).","journal-title":"Schizophr. Res."},{"key":"59259_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00041444-200503000-00001","volume":"15","author":"J Kalman","year":"2005","unstructured":"Kalman, J. et al. Gene expression profile analysis of lymphocytes from Alzheimer\u2019s patients. Psychiatr. Genet. 15, 1\u20136 (2005).","journal-title":"Psychiatr. Genet."},{"key":"59259_CR11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jpsychires.2010.04.011","volume":"44","author":"R Belzeaux","year":"2010","unstructured":"Belzeaux, R. et al. Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J. Psychiatr. Res. 44, 1205\u20131213 (2010).","journal-title":"J. Psychiatr. Res."},{"key":"59259_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/epi.12016","volume":"54","author":"HM Greiner","year":"2013","unstructured":"Greiner, H. M. et al. mRNA blood expression patterns in new-onset idiopathic pediatric epilepsy. Epilepsia. 54, 272\u2013279 (2013).","journal-title":"Epilepsia."},{"key":"59259_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0123-0","volume":"50","author":"HI Woo","year":"2018","unstructured":"Woo, H. I., Lim, S. W., Myung, W., Kim, D. K. & Lee, S. Y. Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis. Exp. Mol. Med. 50, 92 (2018).","journal-title":"Exp. Mol. Med."},{"key":"59259_CR14","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/brain\/awg147","volume":"126","author":"S St\u00fcrzebecher","year":"2003","unstructured":"St\u00fcrzebecher, S. et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain. 126, 1419\u20131429 (2003).","journal-title":"Brain."},{"key":"59259_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2011.12","volume":"1","author":"F Mamdani","year":"2011","unstructured":"Mamdani, F. et al. Gene expression biomarkers of response to citalopram treatment in major depressive disorder. Transl. Psychiatry. 1, e13 (2011).","journal-title":"Transl. Psychiatry."},{"key":"59259_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.112","volume":"2","author":"R Belzeaux","year":"2012","unstructured":"Belzeaux, R. et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl. Psychiatry 2, e185 (2012).","journal-title":"Transl. Psychiatry"},{"key":"59259_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.mayocp.2012.05.019","volume":"87","author":"JI Sirven","year":"2012","unstructured":"Sirven, J. I., Noe, K., Hoerth, M. & Drazkowski, J. Antiepileptic drugs 2012: recent advances and trends. Mayo Clin. Proc. 87, 879\u2013889 (2012).","journal-title":"Mayo Clin. Proc."},{"key":"59259_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca, E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 16, 695\u2013714 (2002).","journal-title":"CNS Drugs."},{"key":"59259_CR19","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1038\/sj.npp.1300245","volume":"28","author":"W Georg","year":"2003","unstructured":"Georg, W. Valproate and GABAergic System Effects. Neuropsychopharmacology. 28, 2050\u20132051 (2003).","journal-title":"Neuropsychopharmacology."},{"key":"59259_CR20","first-page":"392","volume":"35","author":"MM Goldenberg","year":"2010","unstructured":"Goldenberg, M. M. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. P T 35, 392\u2013415 (2010).","journal-title":"P T"},{"key":"59259_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1046\/j.1600-0404.2003.00253.x","volume":"109","author":"Y Tang","year":"2004","unstructured":"Tang, Y. et al. Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study. Acta Neurol. Scand. 109, 159\u2013168 (2004).","journal-title":"Acta Neurol. Scand."},{"key":"59259_CR22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1528-1167.2012.03449.x","volume":"53","author":"T Alapirtti","year":"2012","unstructured":"Alapirtti, T. et al. C-reactive protein and seizures in focal epilepsy: a video-electroencephalographic study. Epilepsia. 53, 790\u2013796 (2012).","journal-title":"Epilepsia."},{"key":"59259_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/seiz.2001.0575","volume":"11","author":"J Peltola","year":"2002","unstructured":"Peltola, J. et al. Indicators of inflammation after recent tonic-clonic epileptic seizures correlate with plasma interleukin-6 levels. Seizure. 11, 44\u201346 (2002).","journal-title":"Seizure."},{"key":"59259_CR24","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/bioinformatics\/btq118","volume":"26","author":"BH Mecham","year":"2010","unstructured":"Mecham, B. H., Nelson, P. S. & Storey, J. D. Supervised normalization of microarrays. Bioinformatics. 26, 1308\u20131315 (2010).","journal-title":"Bioinformatics."},{"key":"59259_CR25","doi-asserted-by":"publisher","first-page":"102056","DOI":"10.1016\/j.plefa.2020.102056","volume":"153","author":"C Rawat","year":"2020","unstructured":"Rawat, C., Shivangi, Kushwaha, S., Sharma, S., Srivastava, A. K. & Kukreti, R. Altered plasma prostaglandin E2 levels in epilepsy and in response to antiepileptic drug monotherapy. Prostaglandins Leukot Essent Fatty Acids. 153, 102056, https:\/\/doi.org\/10.1016\/j.plefa.2020.102056 (2020).","journal-title":"Prostaglandins Leukot Essent Fatty Acids."},{"key":"59259_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/epi.12461","volume":"55","author":"A Rojas","year":"2014","unstructured":"Rojas, A. et al. Cyclooxygenase-2 in epilepsy. Epilepsia. 55, 17\u201325 (2014).","journal-title":"Epilepsia."},{"key":"59259_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/0896-6273(93)90192-T","volume":"11","author":"K Yamagata","year":"1993","unstructured":"Yamagata, K., Andreasson, K. I., Kaufmann, W. E., Barnes, C. A. & Worley, P. F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 11, 371\u2013386 (1993).","journal-title":"Neuron."},{"key":"59259_CR28","first-page":"245","volume":"6","author":"J Chen","year":"1995","unstructured":"Chen, J., Marsh, T., Zhang, J. S. & Graham, S. H. Expression of cyclo-oxygenase 2 in rat brain following kainate treatment. Neuroreport. 6, 245\u2013248 (1995).","journal-title":"Neuroreport."},{"key":"59259_CR29","doi-asserted-by":"publisher","first-page":"24794","DOI":"10.1074\/jbc.271.40.24794","volume":"271","author":"VL Marcheselli","year":"1996","unstructured":"Marcheselli, V. L. & Bazan, N. G. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a plateletactivating factor antagonist. J. Biol. Chem. 271, 24794\u201324799 (1996).","journal-title":"J. Biol. Chem."},{"key":"59259_CR30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.brainres.2005.05.038","volume":"1050","author":"K Kawaguchi","year":"2005","unstructured":"Kawaguchi, K. et al. Cyclooxygenase-2 expression is induced in rat brain after kainate-induced seizures and promotes neuronal death in CA3 hippocampus. Brain Res. 1050, 130\u2013137 (2005).","journal-title":"Brain Res."},{"key":"59259_CR31","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1046\/j.1460-9568.2001.01420.x","volume":"13","author":"T Kunz","year":"2001","unstructured":"Kunz, T. & Oliw, E. H. The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. Eur. J. Neurosci. 13, 569\u2013575 (2001).","journal-title":"Eur. J. Neurosci."},{"key":"59259_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.nbd.2006.02.016","volume":"23","author":"KH Jung","year":"2006","unstructured":"Jung, K. H. et al. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol. Dis. 23, 237\u2013246 (2006).","journal-title":"Neurobiol. Dis."},{"key":"59259_CR33","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.seizure.2007.05.016","volume":"16","author":"A Dhir","year":"2007","unstructured":"Dhir, A., Naidu, P. S. & Kulkarni, S. K. Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure. 16, 691\u2013697 (2007).","journal-title":"Seizure."},{"key":"59259_CR34","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.neuropharm.2009.09.012","volume":"58","author":"EA van Vliet","year":"2010","unstructured":"van Vliet, E. A. et al. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology. 58, 404\u2013412 (2010).","journal-title":"Neuropharmacology."},{"key":"59259_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12035-009-8066-z","volume":"40","author":"AM Hein","year":"2009","unstructured":"Hein, A. M. & O\u2019Banion, M. K. Neuroinflammation and memory: the role of prostaglandins. Mol. Neurobiol. 40, 15\u201332 (2009).","journal-title":"Mol. Neurobiol."},{"key":"59259_CR36","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1124\/mol.107.041210","volume":"73","author":"B Bauer","year":"2008","unstructured":"Bauer, B. et al. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol. Pharmacol. 73, 1444\u20131453 (2008).","journal-title":"Mol. Pharmacol."},{"key":"59259_CR37","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1021\/mp4001102","volume":"10","author":"J Avemary","year":"2013","unstructured":"Avemary, J. et al. Dynamic regulation of P-glycoprotein in human brain capillaries. Mol. Pharm. 10, 3333\u20133341 (2013).","journal-title":"Mol. Pharm."},{"key":"59259_CR38","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.neuropharm.2009.01.009","volume":"56","author":"G Zibell","year":"2009","unstructured":"Zibell, G. et al. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology. 56, 849\u2013855 (2009).","journal-title":"Neuropharmacology."},{"key":"59259_CR39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.brainres.2015.07.005","volume":"1628","author":"H Qosa","year":"2015","unstructured":"Qosa, H., Miller, D. S., Pasinelli, P. & Trotti, D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res. 1628, 298\u2013316 (2015).","journal-title":"Brain Res."},{"key":"59259_CR40","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1021\/acs.molpharmaceut.6b00770","volume":"14","author":"AM Hartz","year":"2017","unstructured":"Hartz, A. M. et al. P-gp Protein Expression and Transport Activity in Rodent Seizure Models and Human Epilepsy. Mol. Pharm. 14, 999\u20131011 (2017).","journal-title":"Mol. Pharm."},{"key":"59259_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1528-1157.1995.tb01657.x","volume":"36","author":"DM Tishler","year":"1995","unstructured":"Tishler, D. M. et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 36, 1\u20136 (1995).","journal-title":"Epilepsia."},{"key":"59259_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/brain\/awf002","volume":"125","author":"SM Sisodiya","year":"2002","unstructured":"Sisodiya, S. M., Lin, W. R., Harding, B. N., Squier, M. V. & Thom, M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain. 125, 22\u201331 (2002).","journal-title":"Brain."},{"key":"59259_CR43","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1093\/brain\/aws147","volume":"135","author":"JY Liu","year":"2012","unstructured":"Liu, J. Y. et al. Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain. 135, 3115\u20133133 (2012).","journal-title":"Brain."},{"key":"59259_CR44","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S1474-4422(13)70109-1","volume":"12","author":"M Feldmann","year":"2013","unstructured":"Feldmann, M. et al. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol. 12, 777\u2013785 (2013).","journal-title":"Lancet Neurol."},{"key":"59259_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neures.2006.06.003","volume":"56","author":"T Takemiya","year":"2006","unstructured":"Takemiya, T. et al. Prostaglandin E2 produced by late induced COX-2 stimulates hippocampal neuron loss after seizure in the CA3 region. Neurosci. Res. 56, 103\u2013110 (2006).","journal-title":"Neurosci. Res."},{"key":"59259_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.eplepsyres.2007.12.008","volume":"79","author":"MS Oliveira","year":"2008","unstructured":"Oliveira, M. S. et al. Cyclooxygenase-2\/PGE2 pathway facilitates pentylenetetrazol-induced seizures. Epilepsy Res. 79, 14\u201321 (2008).","journal-title":"Epilepsy Res."},{"key":"59259_CR47","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1528-1167.2010.02585.x","volume":"51","author":"H Potschka","year":"2010","unstructured":"Potschka, H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia. 51, 1333\u20131347 (2010).","journal-title":"Epilepsia."},{"key":"59259_CR48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.neulet.2008.01.071","volume":"434","author":"HW Yang","year":"2008","unstructured":"Yang, H. W. et al. Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro. Neurosci. Lett. 434, 299\u2013303 (2008).","journal-title":"Neurosci. Lett."},{"key":"59259_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejphar.2009.11.051","volume":"628","author":"K Ambroziak","year":"2010","unstructured":"Ambroziak, K. et al. Exposure to antiepileptic drugs does not alter the functionality of P-glycoprotein in brain capillary endothelial and kidney cell lines. Eur. J. Pharmacol. 628, 57\u201366 (2010).","journal-title":"Eur. J. Pharmacol."},{"key":"59259_CR50","doi-asserted-by":"crossref","unstructured":"Rawat, C., Kushwaha, S., Srivastava, A. K. & Kukreti, R. Peripheral blood gene expression signatures associated with epilepsy and its etiologic classification. Genomics. 112 (218\u2013224), Epub 2019 Mar 1 (2020).","DOI":"10.1016\/j.ygeno.2019.01.017"},{"key":"59259_CR51","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0197-0186(02)00101-8","volume":"42","author":"P Desjardins","year":"2003","unstructured":"Desjardins, P. et al. Induction of astrocytic cyclooxygenase-2 in epileptic patients with hippocampal sclerosis. Neurochem. Int. 42, 299\u2013303 (2003).","journal-title":"Neurochem. Int."},{"key":"59259_CR52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.eplepsyres.2008.12.006","volume":"84","author":"L Holtman","year":"2009","unstructured":"Holtman, L. et al. Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy. Epilepsy Res. 84, 56\u201366 (2009).","journal-title":"Epilepsy Res."},{"key":"59259_CR53","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuroscience.2012.06.002","volume":"220","author":"A Das","year":"2012","unstructured":"Das, A. et al. Hippocampal tissue of patients with refractory temporal lobe epilepsy is associated with astrocyte activation, inflammation, and altered expression of channels and receptors. Neuroscience. 220, 237\u2013246 (2012).","journal-title":"Neuroscience."},{"key":"59259_CR54","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/epi.14505","volume":"59","author":"LD Weidner","year":"2018","unstructured":"Weidner, L. D. et al. The expression of inflammatory markers and their potential influence on efflux transporters in drug-resistant mesial temporal lobe epilepsy tissue. Epilepsia. 59, 1507\u20131517 (2018).","journal-title":"Epilepsia."},{"key":"59259_CR55","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/brain\/awh437","volume":"128","author":"HA Volk","year":"2005","unstructured":"Volk, H. A. & L\u00f6scher, W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain. 128, 1358\u20131368 (2005).","journal-title":"Brain."},{"key":"59259_CR56","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.lfs.2004.02.027","volume":"75","author":"HJ Zhu","year":"2004","unstructured":"Zhu, H. J. & Liu, G. Q. Glutamate up-regulates P-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptor-mediated mechanism. Life Sci. 75, 1313\u20131322 (2004).","journal-title":"Life Sci."},{"key":"59259_CR57","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1399-5618.2007.00361.x","volume":"9","author":"JS Rao","year":"2007","unstructured":"Rao, J. S., Bazinet, R. P., Rapoport, S. I. & Lee, H. J. Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA. Bipolar Disord. 9, 513\u2013520 (2007).","journal-title":"Bipolar Disord."},{"key":"59259_CR58","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.bcp.2014.02.004","volume":"88","author":"YF Chuang","year":"2014","unstructured":"Chuang, Y. F. et al. Valproic acid suppresses lipopolysaccharide-induced cyclooxygenase-2 expression via MKP-1 in murine brain microvascular endothelial cells. Biochem. Pharmacol. 88, 372\u2013383 (2014).","journal-title":"Biochem. Pharmacol."},{"key":"59259_CR59","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.4049\/jimmunol.176.8.5015","volume":"176","author":"R Glauben","year":"2006","unstructured":"Glauben, R. et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176, 5015\u20135022 (2006).","journal-title":"J. Immunol."},{"key":"59259_CR60","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.nbd.2007.02.006","volume":"26","author":"DI Sinn","year":"2007","unstructured":"Sinn, D. I. et al. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol. Dis. 26, 464\u2013472 (2007).","journal-title":"Neurobiol. Dis."},{"key":"59259_CR61","doi-asserted-by":"publisher","first-page":"32569","DOI":"10.1074\/jbc.M503201200","volume":"280","author":"K Yamaguchi","year":"2005","unstructured":"Yamaguchi, K., Lantowski, A., Dannenberg, A. J. & Subbaramaiah, K. Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J. Biol. Chem. 280, 32569\u201332577 (2005).","journal-title":"J. Biol. Chem."},{"key":"59259_CR62","first-page":"155","volume":"42","author":"JM Ford","year":"1990","unstructured":"Ford, J. M. & Hait, W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42, 155\u201399 (1990).","journal-title":"Pharmacol. Rev."},{"key":"59259_CR63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","volume":"55","author":"AH Schinkel","year":"2003","unstructured":"Schinkel, A. H. & Jonker, J. W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug. Deliv. Rev. 55, 3\u201329 (2003).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"59259_CR64","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1124\/jpet.106.102491","volume":"320","author":"S Baltes","year":"2007","unstructured":"Baltes, S., Fedrowitz, M., Tort\u00f3s, C. L., Potschka, H. & L\u00f6scher, W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther. 320, 331\u2013343 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"59259_CR65","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1124\/jpet.103.054197","volume":"307","author":"J Weiss","year":"2003","unstructured":"Weiss, J., Kerpen, C. J., Lindenmaier, H., Dormann, S. M. & Haefeli, W. E. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J. Pharmacol. Exp. Ther. 307, 262\u2013267 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"59259_CR66","first-page":"620","volume":"299","author":"JW Polli","year":"2001","unstructured":"Polli, J. W. et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299, 620\u20138 (2001).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"59259_CR67","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4049\/jimmunol.167.1.350","volume":"167","author":"AA Kaspar","year":"2001","unstructured":"Kaspar, A. A. et al. A distinct pathway of cellmediated apoptosis initiated by granulysin. J. Immunol. 167, 350\u2013356 (2001).","journal-title":"J. Immunol."},{"key":"59259_CR68","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nm.1884","volume":"14","author":"WH Chung","year":"2008","unstructured":"Chung, W. H. et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat. Med. 14, 1343\u201350 (2008).","journal-title":"Nat. Med."},{"key":"59259_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-10-439","volume":"10","author":"M van Iterson","year":"2009","unstructured":"van Iterson, M. et al. Relative power and sample size analysis on gene expression profiling data. BMC Genomics. 10, 439 (2009).","journal-title":"BMC Genomics."},{"key":"59259_CR70","doi-asserted-by":"publisher","first-page":"87ps24","DOI":"10.1126\/scitranslmed.3001628","volume":"3","author":"PI Bacchetti","year":"2011","unstructured":"Bacchetti, P. I., Deeks, S. G. & McCune, J. M. Breaking free of sample size dogma to perform innovative translational research. Sci. Transl. Med. 3, 87ps24 (2011).","journal-title":"Sci. Transl. Med."},{"key":"59259_CR71","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ajmg.b.31062","volume":"153B","author":"B Rollins","year":"2010","unstructured":"Rollins, B. et al. Analysis of whole genome biomarker expression in blood and brain. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 919\u2013936 (2010).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"59259_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-11-589","volume":"11","author":"C Cai","year":"2010","unstructured":"Cai, C. et al. Is human blood a good surrogate for brain tissue in transcriptional studies? BMC Genomics. 11, 589 (2010).","journal-title":"BMC Genomics."},{"key":"59259_CR73","doi-asserted-by":"publisher","first-page":"e38149","DOI":"10.1371\/journal.pone.0038149","volume":"7","author":"E Urich","year":"2012","unstructured":"Urich, E., Lazic, S. E., Molnos, J., Wells, I. & Freskg\u00e5rd, P. O. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS One. 7, e38149 (2012).","journal-title":"PLoS One."},{"key":"59259_CR74","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/jnr.23964","volume":"95","author":"EALM Biemans","year":"2017","unstructured":"Biemans, E. A. L. M., J\u00e4kel, L., de Waal, R. M. W., Kuiperij, H. B. & Verbeek, M. M. Limitations of the hCMEC\/D3 cell line as a model for A\u03b2 clearance by the human blood-brain barrier. J. Neurosci. Res. 95, 1513\u20131522 (2017).","journal-title":"J. Neurosci. Res."},{"key":"59259_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0694-1","volume":"16","author":"W Zhang","year":"2015","unstructured":"Zhang, W. et al. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biol. 16, 133 (2015).","journal-title":"Genome Biol."},{"key":"59259_CR76","doi-asserted-by":"publisher","first-page":"e78644","DOI":"10.1371\/journal.pone.0078644","volume":"9","author":"S Zhao","year":"2014","unstructured":"Zhao, S., Fung-Leung, W. P., Bittner, A., Ngo, K. & Liu, X. Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. PLoS One. 9, e78644 (2014).","journal-title":"PLoS One."},{"key":"59259_CR77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/14740338.2013.827660","volume":"13","author":"RL Maher","year":"2014","unstructured":"Maher, R. L., Hanlon, J. & Hajjar, E. R. Clinical consequences of polypharmacy in elderly. Expert. Opin. Drug. Saf. 13, 57\u201365 (2014).","journal-title":"Expert. Opin. Drug. Saf."},{"key":"59259_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1592-3","volume":"16","author":"C Rawat","year":"2019","unstructured":"Rawat, C., Kukal, S., Dahiya, U. R. & Kukreti, R. Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management. J. Neuroinflammation. 16, 197 (2019).","journal-title":"J. Neuroinflammation."},{"key":"59259_CR79","doi-asserted-by":"crossref","unstructured":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the commission on classification and terminology of the international league against epilepsy. Epilepsia 22, 489\u2013501 (1981).","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"59259_CR80","doi-asserted-by":"crossref","unstructured":"Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the international league against epilepsy. Epilepsia 30, 389\u2013399 (1989).","DOI":"10.1111\/j.1528-1157.1989.tb05316.x"},{"key":"59259_CR81","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer, I. E. et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia 58, 512\u2013521 (2017).","journal-title":"Epilepsia"},{"key":"59259_CR82","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","volume":"51","author":"AT Berg","year":"2010","unstructured":"Berg, A. T. et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005-2009. Epilepsia 51, 676\u2013685 (2010).","journal-title":"Epilepsia"},{"key":"59259_CR83","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ejmech.2013.08.038","volume":"69","author":"A Di Salvo","year":"2013","unstructured":"Di Salvo, A., Dugois, P., Tandeo, D., Peltekian, M. & Kong Thoo Lin, P. Synthesis, cytotoxicity and DNA binding of oxoazabenzo[de]anthracenes derivatives in colon cancer Caco-2 cells. Eur. J. Med. Chem. 69, 754\u2013761 (2013).","journal-title":"Eur. J. Med. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59259-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59259-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59259-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T15:27:23Z","timestamp":1722439643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59259-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["59259"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-59259-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2546"}}